{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:37:06Z","timestamp":1791247026172,"version":"4.1.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Worsening heart failure (HF) is commonly managed in the outpatient setting with adjustments in oral diuretic therapy. The effect of the nonsteroidal mineralocorticoid receptor antagonist finerenone on outpatient worsening HF events in patients with mildly reduced or preserved ejection fraction is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effect of finerenone on outpatient worsening HF events requiring oral diuretic intensification among patients with HF with mildly reduced or preserved ejection fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This is a secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF), a global, multicenter randomized clinical trial. Patients had HF and an ejection fraction of 40% or greater. Data analysis was conducted from September 1 to December 10, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Participants were randomized 1:1 to finerenone or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Primary outcome events (cardiovascular death, HF hospitalization, and outpatient urgent HF visit requiring intravenous diuretic therapy) were centrally adjudicated. In this prespecified analysis, outpatient oral diuretic intensification events were defined as initiations of loop or thiazide diuretic or increases in loop diuretic dosage. The risk of all-cause death following each type of worsening HF event (HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification) and the effect of finerenone on outpatient oral diuretic intensification alone or as part of an extended composite outcome with primary outcome events were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 6001 participants (mean [SD] age, 72.0 [9.6] years; 2732 [46%] female) were enrolled. First worsening HF events included 664 HF hospitalizations, 87 urgent HF visits, and 1250 oral diuretic intensifications. Rates of death were higher following worsening HF: 27.7 (95% CI, 24.3-31.5) per 100 patient-years after HF hospitalization, 13.6 (95% CI, 8.8-21.1) per 100 patient-years after urgent HF visit, and 11.6 (95% CI, 10.2-13.1) per 100 patient-years after outpatient oral diuretic intensification compared with 4.5 (95% CI, 4.2-4.9) per 100 patient-years for patients without worsening HF. Adding outpatient oral diuretic intensification to the primary outcome increased the number of patients experiencing events from 1343 to 2238. Finerenone reduced outpatient oral diuretic intensification alone (hazard ratio [HR], 0.89 [95% CI, 0.80-0.98];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02) and in an extended composite outcome that further included cardiovascular death, HF hospitalization, and urgent HF visit (HR, 0.85 [95% CI, 0.78-0.92];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Outpatient worsening HF events requiring oral diuretic intensification were common, associated with poor prognosis, and reduced by finerenone in patients with HF with mildly reduced or preserved ejection fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04435626\">NCT04435626<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.0016","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T11:32:37Z","timestamp":1740569557000},"page":"370","source":"Crossref","is-referenced-by-count":16,"title":["Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction"],"prefix":"10.1001","volume":"10","author":[{"given":"Jonathan W.","family":"Cunningham","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia","family":"Chatur","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"University of Glasgow, Glasgow, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Llamas Esper\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Cardiol\u00f3gica Aguascalientes, Aguascalientes, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore and Duke-National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[{"name":"Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca ASST Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"University of Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Rohwedder","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"University of Glasgow, Glasgow, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi250001r1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure.","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"hoi250001r2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week.","volume":"81","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"hoi250001r3","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"issue":"9","key":"hoi250001r4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials.","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"hoi250001r5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jchf.2023.04.017","article-title":"Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF.","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"2","key":"hoi250001r6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jacc.2022.04.045","article-title":"Analysis of worsening heart failure events in an integrated health care system.","volume":"80","author":"Ambrosy","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"hoi250001r7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"hoi250001r8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ejhf.71","article-title":"Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT.","volume":"16","author":"Skali","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"hoi250001r9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jchf.2021.01.014","article-title":"Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction: the PARAGON-HF trial.","volume":"9","author":"Vaduganathan","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"17","key":"hoi250001r10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF.","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"hoi250001r11","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.123.066506","article-title":"Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial.","volume":"148","author":"Chatur","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"hoi250001r12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial.","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hoi250001r13","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial.","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"hoi250001r14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi250001r15","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/ejhf.2018","article-title":"Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium.","volume":"22","author":"Abraham","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"hoi250001r16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of loop diuretics with thiazide-type diuretics in heart failure.","volume":"56","author":"Jentzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"hoi250001r17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction.","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi250001r18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure.","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi250001r19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamacardio.2017.5250","article-title":"Outpatient worsening heart failure as a target for therapy: a review.","volume":"3","author":"Greene","year":"2018","journal-title":"JAMA Cardiol"},{"key":"hoi250001r20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity.","author":"Packer","year":"2024","journal-title":"N Engl J Med"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2830807\/jamacardiology_cunningham_2025_oi_250001_1743523583.26463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:00:45Z","timestamp":1744196445000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2830807"}},"subtitle":["A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.0016","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}